Document
Determination of Regulatory Review Period for Purposes of Patent Extension; Correction of Notices-ANDEMBRY; ANZUPGO; ANKTIVA; BIZENGRI; BRINSUPRI; DAYVIGO
The Food and Drug Administration (FDA) is announcing corrections to the notices of Determination of Regulatory Review Period for Purposes of Patent Extension for ANDEMBRY; ANZUP...
SUPPLEMENTARY INFORMATION:
FDA announced the regulatory review period determination for BRINSUPRI in the
Federal Register
of August 10, 2026 (91 FR 51493). In Document No. 2026-16247, on page 51494, second column, in the first paragraph of section II., the Determination of Regulatory Review Period portion of the document, the following correction is made:
FDA has determined that the applicable regulatory review period for BRINSUPRI is 2,925 days. Of this time, 2,681 days occurred during the testing phase of the regulatory review period, while 244 days occurred during the approval phase.
FDA announced the regulatory review period determination for DAYVIGO in the
Federal Register
of August 10, 2026 (91 FR 51494). In Document No. 2026-16246, on page 51495, third column, in the first paragraph of section II., the Determination of Regulatory Review Period portion of the document, the following correction is made:
FDA has determined that the applicable regulatory review period for DAYVIGO is 3,116 days. Of this time, 2,648 days occurred during the testing phase of the regulatory review period, while 468 days occurred during the approval phase.
FDA announced the regulatory review period determination for BIZENGRI in the
Federal Register
of August 17, 2026 (91 FR 53261). In Document No. 2026-16713, on page 53262, second column, in the first paragraph of section II., the Determination of Regulatory Review Period portion of the document, the following correction is made:
FDA has determined that the applicable regulatory review period for BIZENGRI is 2,912 days. Of this time, 2,636 days occurred during the testing phase of the regulatory review period, while 276 days occurred during the approval phase.
FDA announced the regulatory review period determination for ANKTIVA in the
Federal Register
of September 9, 2026 (91 FR 57350). In Document No. 2026-18297, on page 57351, third column, in the first paragraph of section II., the Determination of Regulatory Review Period portion of the document, the following correction is made:
FDA has determined that the applicable regulatory review period for ANKTIVA is 3,925 days. Of this time, 3,224 days occurred during the testing phase of the regulatory review period, while 701 days occurred during the approval phase.
FDA announced the regulatory review period determination for ANZUPGO in the
Federal Register
of September 9, 2026 (91 FR 57355). In Document No. 2026-18298, on page 57356, first column, in the first paragraph of section II., the Determination of Regulatory Review Period portion of the document, the following correction is made:
FDA has determined that the applicable regulatory review period for ANZUPGO is 3,535 days. Of this time, 3,169 days occurred during the testing phase of the regulatory review period, while 366 days occurred during the approval phase.
FDA announced the regulatory review period determination for ANDEMBRY in the
Federal Register
of September 9, 2026 (91 FR 57356). In Document No. 2026-18300, on page 57357, third column, in the first paragraph of section II., the Determination of Regulatory Review Period portion of the document, the following correction is made:
FDA has determined that the applicable regulatory review period for ANDEMBRY is 2,531 days. Of this time, 1,918 days occurred during the testing phase of the regulatory review period, while 613 days occurred during the approval phase.
Grace R. Graham,
Deputy Commissioner for Policy, Legislation, and International Affairs.